Using nafamostat mesilate anticoagulation for continuous renal replacement therapy in high bleeding risk patients: a systematic review and meta-analysis

Author:

Zhang Yi1,Chen Xianggping1,Lao Yuewen1,Li Qiujing1,Wang Ping1,Chen Li1,Zhuang Yiyu1,Gong Xiaoyan1

Affiliation:

1. Zhejiang University School of Medicine

Abstract

Abstract Objectives: The purpose of this systematic review is to evaluate the safety and efficacy of nafamostat mesilate (NM) for continuous renal replacement therapy in high bleeding risk patients. Methods: We performed a comprehensive search on PubMed, Embase, CINAHL, Web of Science, the Cochrane Library, and CNIK from inception to May 1, 2022. Two reviewers independently screened, selected, and extracted data.A meta-analysis was conducted using RevMan 5.3 software. The systematic review protocol was registered. Results: 7 studies with 639 high bleeding risk patients were included for review including 4RCTs and 3 retrospective cohort studies. The anticoagulant in the control group of all included studies was anticoagulation-free. Compared with the baseline data, the activated partial thromboplastin time of the NM group was shortened at the end of observation (MD -12.16, 95% CI -23.70 to -0.62, p= 0.04). NM for CRRTsignificantly extended filter life (MD 9.65, 95% CI 5.60 to 13.71, p< 0.00001)and reduced mortality compared with anticoagulation-free treatment (RR 0.76, 95% CI 0.64 to 0.90, p= 0.002). No significant difference was observed in the incidence of bleeding complications (RR 1.16, 95% CI 0.59 to 2.26, p= 0.67) and total duration of CRRT (MD 12.65, 95% CI -6.79 to 32.09, p= 0.20) between the groups. Subgroup analysis showed the same results except for the mortality outcome. Conclusions: For patients at high bleeding risk undergoing CRRT, NM is a better anticoagulation option. More multicenter RCTs with large samples are required to validate and compare the effects of NM anticoagulants.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3